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Abstract
Noninvasive methods are strongly needed to detect and quantify not only tumor growth in murine tumor models
but also the development of vascularization and necrosis within tumors. This study investigates the use of a new
imaging technique, flat-panel detector volume computed tomography (fpVCT), to monitor in vivo tumor progres-
sion and structural changes within tumors of two murine carcinoma models. After tumor cell inoculation, single
fpVCT scans of the entire mice were performed at different time points. The acquired isotropic, high-resolution
volume data sets enable an accurate real-time assessment and precise measurements of tumor volumes. Spread-
ing of contrast agent–containing blood vessels around and within the tumors was clearly visible over time. Further-
more, fpVCT permits the identification of differences in the uptake of contrast media within tumors, thus
delineating necrosis, tumor tissues, and blood vessels. Classification of tumor tissues based on the decomposition
of the underlying mixture distribution of tissue-related Hounsfield units allowed the quantitative acquisition of ne-
crotic tissues at each time point. Morphologic alterations of the tumor depicted by fpVCT were confirmed by his-
topathologic examination. Concluding, our data show that fpVCT may be highly suitable for the noninvasive
evaluation of tumor responses to anticancer therapies during the course of the disease.
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Introduction
To assess the increasing amounts of novel, targeted therapies to treat
solid tumors in clinically relevant murine models, it is desirable to
monitor tumor progression in detail during the course of the disease.
At present, longitudinal studies of mouse cancer models require large
cohorts because autopsy at different tumor stages has been the only
reliable method to evaluate tumor progression and anticancer treat-
ment efficacy. The assessment of tumor growth in small animal models
has frequently relied on the rather imprecise calculations of tumor vol-
umes by caliper measurements of maximum tumor diameter, tumor
minor axis, and tumor length either during or toward the end of an ex-
periment [1]. However, the assessment of therapy efficacy requires the
accurate measurement of changes in tumor volume during the course
of the disease. Therefore, techniques have been developed, which en-
able imaging and exact monitoring of tumor growth and progression
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in vivo, such as magnetic resonance imaging (MRI) [2], ultrasound
[3–5], computed tomography (CT) [6,7], and nuclear imaging [8,9].
Each modality possesses a unique combination of strengths and weak-
nesses that affects their selection for use in a particular study.
Here, we introduce a novel approach, flat-panel detector volume com-
puted tomography (fpVCT), which allows three-dimensional (3D) visu-
alization of anatomic structures with isotropic imaging resolution
[10,11]. Compared with other imaging modalities, fpVCTenables shorter
scanning times of approximately 8 seconds. In addition, the mouse skel-
eton can be visualized in detail and with clear contours [12–14]. Flat-
panel detector volume computed tomography therefore shows excel-
lent sensitivity in detecting skeletal lesions. Using this method, we recently
determined the accurate localization, size determination, and assessment
of the progression of osteolytic bone lesions within the mouse skeleton in
a metastatic breast tumor model [15]. Information about tumor volume
changes is of great value in the assessment of the efficacy of tumor ther-
apies. However, the development of blood vessels and necrotic tissues
within these tumors are likewise important parameters in such studies.
We evaluated, therefore, the use of the fpVCTmethod to monitor tumor
growth and the morphologic changes in both orthotopic and subcutane-
ous severe combined immunodeficient (SCID) mouse models of MDA-
MB-231 and R30C mammary carcinoma cells, respectively. Here, we
demonstrate that fpVCTexhibits excellent sensitivity and accuracy in vi-
sualizing tumors and allows a precise real-time assessment of tumor growth
by the detection of structural alterations within the tumors over time.
Materials and Methods
Cell Lines
The estrogen-independent human breast cancer cell line MDA-
MB-231 was obtained from the American Type Culture Collection
(Rockville, MD) and was maintained at 37°C in a humidified atmo-
sphere containing 5% CO2 in DMEM supplemented with 10% fetal
calf serum and 1% L-glutamine (all from PAN Systems, Aidenbach,
Germany). The human mammary tumor cell line R30C was kindly
provided by Dr. Ralf Bargou, Max-Delbrueck-Centre For Molecular
Medicine, Berlin, Germany [6]. Cells were maintained in RPMI 1640
with GlutaMAX-I (Invitrogen, Karlsruhe, Germany), with 25 mM
HEPES supplemented with 10% heat-inactivated fetal calf serum,
0.5 mM sodium pyruvate, 60 U/ml penicillin, and 60 μg/ml strepto-
mycin. Cells were regularly certified free of mycoplasma contamination.
Tumor cells were harvested near confluence by brief trypsinization in
0.25% trypsin–EDTA solution (Gibco, Carlsbad, CA), washed sev-
eral times, and placed in sterile PBS shortly before implantation.
Animals
All animals were handled according to German regulations for ani-
mal experimentations, and all animal protocols were approved by the
administration of Lower Saxony, Germany. For this study, SCID
mice, strain C.B-17/Ztm-scid, were used and the latter were main-
tained in a sterile environment in special cages with filter huts and
in a Scantainer (Scanbur, Koge, Denmark). Cages, bedding, and wa-
ter were autoclaved, and the food was gamma-irradiated. Immunode-
ficiency of SCID mice was verified by measuring serum immunoglobulin
levels using an enzyme-linked immunosorbent assay.
Tumor Cell Implantation
For orthotopic tumor cell implantation, female SCID mice were
anesthetized by peritoneal injection of 75 mg/kg ketamine hydro-
chloride with 15 mg/kg xylazine. A total of 1 × 106 MDA-MB-
231 cells suspended in 25 μl of sterile PBS were implanted with
an insulin syringe, 29-gauge × 0.5 in. (Becton Dickinson, Heidelberg,
Germany) very slowly into the mammary fat pad of the fourth mam-
mary complex. The cells were implanted to visibly infiltrate the
breast tissue. The needle was slowly withdrawn after a 1-minute de-
lay. The mammary gland was then returned, and the incision was
closed using an interrupted Vicryl suture for the skin (5/0; Ethicon,
Norderstedt, Germany). A total of 2 × 106 R30C cells were subcu-
taneously injected into both flanks of the SCID mice. All manipula-
tions were conducted under aseptic conditions using a laminar flow
hood. All animals tolerated the procedure well. After implantation,
mice were inspected daily for body weight loss, general condition,
and tumor formation.
Flat-Panel Detector Volume Computed Tomography Imaging
Mice were imaged with a fpVCT, a nonclinical volume CT proto-
type (GE Global Research, Niskayuna, NY). They were anesthetized
with vaporized isoflurane at 0.8% to 1% concentration throughout
the imaging session, centered on the fpVCT gantry axis of rotation,
and placed perpendicularly to the z-axis of the system, so that it was
possible to scan the whole mouse with one rotation. An iodine-
containing contrast agent, Isovist 300 (at 150 μl per mouse; Bayer-
Schering, Berlin, Germany), was applied intravenously approximately
30 seconds before scan.
Flat-panel detector volume computed tomography consists of a
modified circular CT gantry and two amorphous silicon flat-panel
X-ray detectors each of 20.5 × 20.5 cm2 with a matrix of 1024 ×
1024, 200-μm detector elements. The fpVCT works in a step-and-
shoot acquisition mode. Standard z-coverage of one step is 4.21 cm.
All data sets were acquired with the same protocol: 1000 views per
rotation, 8 seconds of rotation time, 360 used detector rows, and
80 kVp and 100 mA. A modified Feldkamp algorithm was used
for image reconstruction resulting in isotropic high-resolution vol-
ume data sets (512 × 512 matrix, with an isotropic voxel size of ap-
proximately 100 μm).
Tumor Segmentation and Generation of a Tumor
Density Histogram
To visualize morphologic changes within the tumor, tumors were
segmented by a region-growing algorithm. Tumor capsules and pe-
ripheral blood vessels having a higher density than the tumor tissue
were borders of segmentation. In the next step, a histogram was gen-
erated, displaying the relative occurrence of voxels over their Houns-
field values within the tumor. Thus, the histogram represents the
percentage of tumor tissue comprising the same density versus the
measured density in Hounsfield units (HU). For tumor segmenta-
tion and computing, histogram data sets were analyzed with voxtools
3.0.64 Advantage Workstation 4.2 (GE Healthcare, Buckingham-
shire, UK). For the evaluation of fpVCT-based volumetry, commer-
cially available spherical phantoms (Spherotech, Fulda, Germany) of
different materials and with known diameters were used.
Autopsies and Histologic Analysis
At the end of the experiment, autopsies of SCID mice were per-
formed, tumors were excised and weighed, and the abdomen and
thoracic cavity were examined systematically for the presence of
metastases. At autopsy and after excision, visible tumors were exter-
nally measured with a caliper. Tumors were collected and placed in
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phosphate-buffered 4% formalin for 16 hours at room temperature
and were embedded in paraffin. Tissue sections (2.5 μm) were ob-
tained, stained with hematoxylin and eosin (H&E), and inspected by
routine microscopic examinations.
Statistical Analysis
Five MDA-MB-231 tumors were analyzed for tumor growth rates
and for morphologic alterations, respectively. Statistical analyses were
performed using Microsoft Office Excel 2003 version 11.0 (Microsoft
Corporation, Redmond, WA). All data were expressed as mean ± SD.
Results
Assessment of Mammary Carcinoma Growth by fpVCT
To investigate the use of fpVCT as a noninvasive imaging tool
to monitor tumor growth and progression, whole bodies of breast
tumor–bearing mice were scanned using fpVCT in combination with
an iodine-containing contrast agent at certain time points. Orthoto-
pic transplantation of MDA-MB-231 human breast tumor cells re-
sulted in tumor development in the mammary gland of all five mice.
As shown in Figure 1A, fpVCT enabled the visualization of the en-
largement of the mammary carcinomas in 3D over time. By both the
precise delineation of the tumor in vivo and the virtual isolation of
the tumor from the fpVCT data sets, tumor volumes were calculated
automatically by considering all three dimensions (Figure 1B). These
calculations allowed the generation of precise growth kinetics for
each tumor over time (Figure 1C ). Volumes of the tumors ranged
between 63 and 486 mm3 at the end of the experiment and showed
a change in weekly mean growth rates, 128 ± 80% and 68 ± 33%
between days 21 and 28 and between 35 and 42 days, respectively
(Figure 1C ).
Using traditional caliper measurements, the length (L), width (W ),
and height (H ) of each tumor were analyzed. Here, the presuming
ellipsoid volume that provides the most precise measurement of tumor
mass [16] was calculated from the following formula: 0.5 · L · W · H .
Because most of the tumors developed either an irregular, nonellipsoid
shape, or multiple lobes, tumor volumes calculated from the fpVCT
data sets were generally 10.0 ± 5.85% larger compared with standard
caliper measurements of volumes of postmortem-dissected tumors
(Figure 1D). Small tumors showed the least discrepancy with a
1.8% deviation from tumor volumes determined using fpVCT. To as-
sess the reliability of the automated process for the measurement of
tumor volumes after tumor segmentation, two spherical phantoms
with known diameters of 3.00 and 3.18 mm were scanned using
fpVCT. Their volumes were determined in a manner similar to that
performed for the determination of tumor volume using the region-
growing tool; this method correlated very precisely with the mathemat-
ically determined volume. Relative measurement errors were between
0.99% and 1.01%.
Monitoring Tumor Blood Vessel Development by fpVCT
Furthermore, follow-up examination of mice was performed using
fpVCT to assess fpVCT applicability to monitor the recruitment and
formation of tumor vessels over time. As presented in Figure 2, contrast
Figure 1. Growth rate of an orthotopically implanted tumor depicted in vivo by 3D reconstructions of fpVCT data sets. (A) Representa-
tions of volume rendering of skin in the tumor area after virtual removal of fur. Visualization of the enlargement of a representative
mammary carcinoma by repeated fpVCT scans in combination with contrast agent 21, 28, 35, and 42 days after MDA-MB-231 cell
implantation. (B) Corresponding semiautomatically segmented tumors. The indicated volumes were automatically determined. (C)
Growth rates of five MDA-MB-231 tumors for 3 weeks. (D) Comparison of automatically determined tumor volumes using fpVCT data
sets (rhombuses) with caliper measurements postmortem (squares). Although tumor volumes were underestimated by caliper measure-
ments, the data show the proportionality between both methods.
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agent–containing blood vessels with sizes greater than 150 μm in di-
ameter were monitored over time in arbitrary planes of the tumor pe-
riphery by applying different visualization protocols of the 3D fpVCT
data sets. Only when the content of the contrast agent within the vas-
culature is high the smaller blood vessels can be detected, although size
cannot be assessed. Furthermore, tumor-infiltrating vessels could be
clearly visualized, and their development was followed using fpVCT
(Figure 2, A–C). The rate of vascularization in the orthotopic tumors
increased between 3 and 5 weeks after tumor implantation (Figure 2A).
After 3 to 4 weeks, the vessels possessed small diameters in the tumor
periphery and in the tumor center. One week later, the vessels showed
the greatest enlargement in diameter with highest density. However,
after week 6, vessel density decreased, particularly in the tumor center,
although increasing vessel diameter could be observed (Figure 2B, left).
In comparison, fpVCT scans revealed that subcutaneous R30C
breast tumors recruited blood vessels later in the disease process
and developed a regular distribution of peripheral blood vessels cov-
ering nearly the whole surface of the tumor (Figure 2C ). Only after
25 days did blood vessels become visible; a dense network increased
continuously thereafter. In the 2D maximum intensity projection
(MIP), the density of the tumor is indicative of a diffuse lattice of ves-
sels, which crosses the tumor (Figure 2B, right).
Furthermore, the origin and distribution of blood vessels supply-
ing both the orthotopic and subcutaneous tumors were defined using
fpVCT (Figure 2, D and E ). In both tumor models, the afferent
blood vessels were primarily supplied by a connection to the upper
lumbar artery (Figure 2D), whereas the efferent blood vessels were
observed to discharge into the brachiocephalic vein (Figure 2E ).
Thus, the dynamic process of blood vessel constitution during tumor
growth and the reorganization and loss of central blood vessels could
be qualitatively imaged using fpVCT.
Qualitative and Quantitative Analysis of Tumor Density
Ratios In Vivo
To quantify and visualize morphologic structures such as necrotic tis-
sue, intact tumor tissues, and blood vessels within tumors, several steps
of a semiautomatic procedure were performed. First, the tumor was
segmented out of the entire 3D fpVCT data set as shown in Figure 3,
Figure 2. Tumor vessel development over time visualized in vivo using 3D fpVCT data sets. (A) Depiction of contrast agent–containing
tumor vessels and their distribution and bifurcations both in the periphery and within a developing orthotopic mammary tumor by re-
peated fpVCT scans of a representative SCID mouse. Tumor vessels possessed small diameters on day 21 and their density increased
by day 28. Tumor vessels appeared most enlarged after 35 days, followed by a decrease in the number of vessels with high density 1
week later. The tumor is framed. (B) In an MIP presentation of the final scan, blood vessels within the tumor were not visible, suggesting
the loss of central blood vessels due to necrotic tissue after this period (left). One kidney is indicated (K). (C) Tumor vessel formation of a
representative subcutaneous mammary carcinoma in combination with contrast agent (right). Tumor vessels were hardly visible 20 days
after R30C tumor cell implantation and appeared after 25 days. The density of vessels around the tumor increased after 28 days and
even more after 31 days. (B) An MIP presentation of vessel densities within the tumor indicates that a diffuse lattice of vessels infiltrated
the tumor tissue (right). (D) Visualization of a single blood vessel supplying the orthotopic tumor (framed) and (E) the venous port of the
subcutaneous tumor. The tumor is framed. (D) In the dorsal aspect of a tumor-bearing mouse after orthotopic implantation of MDA-MB-
231 cells, a blood vessel (black arrow) coming from the tumor (white arrow) can be traced to the kidneys (K). In a higher magnification
and after subtraction of the spine, a connection (arrowhead) between the tumor vessel (arrow) and the upper lumbar artery is visible.
Aorta (A) and vena cava (V) are depicted as parallel running structures. (E) A large efferent vessel (white arrow) of the subcutaneous
tumor (black arrow) discharges in the brachiocephalic vein (arrows) as shown in detail (right).
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A–C . Next, a histogram of the relative frequencies of different densities
in HU within the observed volume was created (Figure 3, D–F ). In-
flection points, defined as points on the curve at which the curvature
changes its sign, were automatically determined in those cases in
which the histogram did not fit a Gaussian distribution pattern (Fig-
ure 3E ). Because the density values between two inflection points
represent a particular portion of the entire volume, they were illus-
trated by various colors. Most of the examined tumors showed typ-
ical tripartite histograms that consist of a portion of low density,
often in the negative HU range depicted in blue, a major portion
of middle density, depicted in red, and a smaller portion of high den-
sity (up to 500 HU) depicted in white (Figure 3E ). Hence, the major
difference between these portions was the distinguishable X-ray ab-
sorption pattern due to the specific receptivity toward the contrast
agent in specific tissues. Under the assumption that these different
portions are the sum of at least three overlapping normal distribu-
tions, the histogram was predicted to be a mixed Gaussian distribu-
tion (Figure 3F ).
To characterize the different underlying normal distributions within
the tumor and their percentages per total volume, we implemented
a specific expectation maximization (EM) algorithm as described
by Dullin [17] in which the portion percentage, the mean, and
the SD of the now-separated single distributions within the entire vol-
ume of the segmented tumor are estimated. Next, we assumed that
the different distributions within the histogram were a consequence
of the different behaviors of the tumor tissue due to its biologic re-
ceptivity toward the contrast agent. A tumor with necrotic portions
consists ideally of three different types of tissues: 1) normal tumor
tissue that takes up small amounts of the applied contrast agent be-
cause of sufficient vascularization, 2) necrotic tumor tissue with a
more waterlike density that assimilates no contrast agent, and 3) con-
trast media–containing blood vessels. Therefore, we correlated single
distributions of the histogram with the approximate amount of ne-
crotic tissue, depicted in blue as a low-density region and intact tu-
mor tissues within the segmented tumor, depicted in red (Figure 3,
E–I ). The most precise determination of the amount of single por-
tions was observed in the minimal overlapping distributions with
well-separated peaks. Initially, this pattern was generated from the
distinct absorption of the contrast agent. Otherwise, a clear separa-
tion would be disturbed by the partial volume effect, leading to
Figure 3. Quantitative and qualitative analyses of the density ratios within an orthotopic tumor in vivo using fpVCT. (A) A 3D volume-
rendering image of the tumor in situ (arrow) 42 days after orthotopic implantation of MDA-MB-231 cells. Superficial layers were sub-
tracted. (B) A 2D fpVCT image of the same mouse in a coronal view; note that the tumor is framed. (C) Semiautomatic segmentation of
the tumor after subtraction of all additional data sets of the mouse. (D) Histogram of the percentage of tumor tissue within the tumor
volume versus its density in HU measured by fpVCT. (E) Inflection points of the curve were determined automatically. Density values
between two inflection points (divided by black marks) belong to a specific density portion, marked with different colors. The blue
distribution indicates a fraction of low density, red indicates a portion of an intermediate-density range, and white fraction indicates
the portion of highest density. (F) These density portions within the tumor volume were assumed to be three overlapping Gaussian
distributions that possessed their specific peaks in different density regions of the histogram. (G–I) Volume-rendering images of the
tumor in three serial median slices. Distribution of the colors corresponds to the colors of the histogram and suggests to represent
the central necrotic area in blue as a low-density region, the surrounding tumor tissue in red, and the contrast agent–containing blood
vessels in white with the highest density on the surface of the tumor. Scale bar in (I), 5 mm.
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merging at the boundaries of both low- and the high-density distri-
butions within the central portion.
Due to the high spatial resolution of the 3D fpVCT data sets, vir-
tual serial sections of the tumor with a distance of 200 μm were gen-
erated. Corresponding to the colors used for the histogram (Figure 3,
E and F ), the sections were dyed in blue and red to show the exact
localization of both the low- and high-density areas within the tumor
having central necrosis and surrounding intact tumor tissue, respec-
tively (Figure 3, G–I ).
Depiction of Tumor Density Ratios by fpVCT Compared with
Histologic Examination
To validate the finding that different tissues within the tumor can
be classified using fpVCT in vivo, we compared the density profiles
of tumors generated by the 3D depiction of the fpVCT data sets with
both macroscopic and histologic examinations. As shown in Figure 4,
A–D, after 6 weeks, fpVCT data sets revealed that low-density areas
corresponding to necrosis were primarily located in the center of
orthotopic tumors and were surrounded by tissue of higher density
(Figure 4C ). Macroscopic examination of the same tumor shortly
dissected after fpVCT scan confirmed the presence of necrotic areas
within the center of the tumor (Figure 4D). Therefore, fpVCT
images reliably depict density ratios of tumors with high spatial res-
olution and thereby allow classification of tumor tissues in vivo.
By comparing histologic cross sections of the excised tumors with
corresponding serial sections of the fpVCT images (Figure 4E ), we
could show that the morphologic structures closely correlated to the
corresponding in vivo data acquired using fpVCT (Figure 4E , detailed
view). The central area of necrosis as shown by histologic examination
is clearly visible using fpVCT (Figure 4E , left) and is thereby predict-
able in vivo. Even discrete features, such as a small blood vessel appear-
ing within the necrotic area and the surrounding intact tumor tissue,
were depicted authentically (Figure 4E , detailed view).
Determination of Longitudinal, Morphologic Changes of Both
Necrotic and Nonnecrotic Tumors Using fpVCT In Vivo
By an exact delineation of density and density ratios within the
tumors and the quantification of the main components, such as tu-
mor tissue, necrotic tissue, and blood vessels, the amount of necrosis
was quantified based on the histograms for each scan time (Figure 5).
A representative, orthotopically implanted tumor was chosen to il-
lustrate the morphologic alterations that are characteristic of this tu-
mor model (Figure 5, A and B). Twenty-one days after the orthotopic
implantation of MDA-MB-231 cells, the major tumor volume dis-
played a low density. These findings can be explained by the missing
receptivity toward the contrast agent as a consequence of a depauper-
ate tumor blood vessel system. After 28 days, the histogram showed
the characteristic shift to a positive HU range (Figure 5A) that cor-
relates with the occurrence of more compact structures within the
tumor (Figure 5B). In the histograms for days 21 and 28 (Figure 5A),
only single components of the entire tumor volumes were depicted.
After these first time points, the curves shift gradually to the negative
HU range, suggestive of the development of necrosis. During this
observation period, the curves of the histograms divide explicitly into
at least two portions, suggesting the separation of a larger necrotic
area and a smaller area of intact tumor tissue (Figure 5A). The cor-
responding 3D visualizations of the tumor were in agreement with an
increase in a central area of less density (Figure 5B). After the imple-
mentation of the self-developed EM algorithm, the portions of necro-
sis after both 35 and 42 days constituted 49% and 51% of the entire
tumor volume, respectively. The increase in necrosis between weeks 5
and 6 was accompanied by a decrease in intact tumor tissue from 27%
to 20%. Furthermore, an increase of the high-density tumor portion
was observed in accordance with an increase of vessel diameter, as de-
picted in Figure 2A.
As shown in Figure 6A, an overlay of the histograms from all scans
of the orthotopic tumor depicts the sum of morphologic changes at
different time points. The development of necrosis, which constitutes
the main portion of the tumor after 35 days, is indicated by the incre-
mental shifts of the peaks of the histogram to the negative HU range.
In addition, the different peaks and breadths of the curves for each
time point represent the amount of voxels within the histograms
and, hence, show tumor growth by an increase in volume. To deter-
mine the extent of necrosis in the orthotopic mammary carcinoma
model, five mice were analyzed on the day of dissection by the equal
application of contrast agent 28 seconds before the scan. All assessed
tumors showed distinct central necrosis with a mean portion of 49 ±
6%. Note that the smallest tumor showed the smallest portion of
necrosis (data not shown).
In contrast, the subcutaneous tumor showed no central necrosis
during the observation period as clearly depicted in Figure 5, C and
D. Only the broadening of the curve in the histogram after 31 days
indicates a slow separation of density portions, suggesting the develop-
ment of necrosis (Figure 5C ). Although only a single component was
recognized after the application of the EM algorithm, small, scattered
necrotic foci could be visualized by 3D depiction (Figure 5D).
In accordance with these results, the overlay of the histograms
from all scans of the nonnecrotic tumor displayed no development
of a primary necrotic portion. Figure 6B, the nonnecrotic tumor
showed a shift of peaks toward the positive HU sector during the
observation period.
Comparison of these fpVCT images of the final scans with the
corresponding histologic sections confirmed the presence of a large
central area of necrosis in the orthotopic tumor (Figure 6, C–E )
and the predominate existence of intact tumor tissue in the subcuta-
neous tumor (Figure 6, F–H ). Furthermore, these results underscore
the reliability and the potential of this technique to both detect and
quantify morphologic alterations within a defined tumor.
Discussion
In this study, we demonstrated that the use of volume CT with
flat-panel detectors enabled the noninvasive determination of mor-
phologic changes within two estrogen-independent mammary carci-
noma tumor models. Invasive and highly dedifferentiated human
MDA-MB-231 mammary carcinoma cells were implanted into the
orthotopic environment of the mouse mammary fat pad, whereas hu-
man mammary carcinoma R30C cells were injected subcutaneously
into mice, a rather nonphysiological environment [6]. Weekly scan-
ning using fpVCT revealed fast-growing MDA-MB-231 mammary
carcinomas in all SCID mice and precise determination of their
growth rates. Generally, tumor growth in murine tumor models has
been determined by intravital measurement of the tumor using a cal-
iper [18,19]. This technique is rather limited not only because it de-
mands the expertise of the researcher but also because it is only
applicable for subcutaneously or superficially growing tumors. Only
approximate tumor volumes can be determined using this method
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Figure 4. Comparison of images generated by fpVCT with both macroscopic and histopathologic examinations. (A) A 3D fpVCT image of
an orthotopic mammary tumor (arrow) 6 weeks after tumor cell implantation in situ. (B) Macroscopic appearance of the tumor (arrow)
in situ at the time of dissection. (C) An fpVCT-generated representative 3D central section depicts the halves of the tumor with their
density profile: the central necrotic area (blue, black arrow) and intact tumor tissue, including densely packed mammary gland tissue
(red, white arrow). (D) Macroscopic appearance of a central slice of the dissected tumor confirmed the existence of necrotic tissue
(black arrow) between the intact tumor and mammary gland tissues (white arrow). Note that the analog distribution of these features
in the fpVCT image is indicated with arrows in (C). (E) An fpVCT volume-rendering presentation of a different mouse bearing an ortho-
topic mammary tumor (blue). (E, detailed view, left) Serial sections of the tumor virtually cut off the fpVCT data sets that were generated
with contrast agent on the day of dissection. Visualization of densities within tumor sections demonstrates a distinct central necrotic
region (blue), surrounding tumor tissue (red), and a cross section of a blood vessel (top left, arrow). (E, detailed view, top right) Median
paraffin section of the same tumor stained with H&E closely corresponds to the predicted distribution of the morphologic features
necrosis (N), intact tumor tissue (T), and a vessel (V, arrow) depicted by the fpVCT data sets as shown in (E, top left). At a 2.5-fold higher
magnification (E, bottom right), the display window according to the frame in (E, bottom left) shows the occurrence of intact tumor
tissue (T) between an area of central necrosis (N). Scale bars: bottom and top left, 4 mm; top right, 3 mm; bottom right, 800 μm.
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because only two dimensions are measured and the theoretical thick-
ness of the skin must be subtracted [20]. Image reconstruction from
fpVCTmeasurements, however, results in isotropic high-resolution 3D
volume data sets, enabling the determination of tumor volumes in vivo
with high precision and, thus, allowing the objective acquisition of
tumor growth kinetics in longitudinal studies. To evaluate preclinical
treatment responses to anticancer therapies, further information re-
garding tumor microvasculature and the occurrence of necrosis are
of great interest. Here, we demonstrate that short, single fpVCT scans
at certain time intervals allow the precise observation of the develop-
ment of structural alterations within tumors of both cancer models.
Our results were confirmed by histologic examination and revealed
that orthotopic mammary carcinomas developed central necrotic areas
over time, whereas only small, scattered necrotic areas were observed in
the subcutaneous tumor.
Similar to fpVCT, 3D ultrasound microimaging generates 3D data
sets and has been shown to determine exact tumor volumes in living
mice over time. A previous study showed that by correlating ultrasound
image texture with cell density, both the foci of necrotic areas and blood
vessel distribution in mouse prostate cancer could be depicted [5]. This
technique has a high spatial resolution comparable to fpVCT; however,
it is primarily used for the analysis of soft tissues that do not require the
use of contrast agent. Compared with fpVCT, ultrasound uses a smaller
penetration depth and has a smaller field of view. Furthermore, it re-
quires the depilation of fur before image acquisition.
Micro CT (μCT), with a very high spatial resolution of 5 to 10 μm
[21], generates 3D data sets comparable to fpVCT and ultrasound;
however, it is accompanied by the need for high doses of radiation
and long scanning times [22,23]. A precise calculation of tumor vol-
umes in combination with a good soft tissue contrast agent is feasible
using MRI [24–26]. Furthermore, Overhauser-enhanced MRI or
[19F]-perfluorocarbon MRI allow the direct measurement of oxygen
concentrations within the tumor, which reflects the hypoxic status
of the tissue [27,28]. Moreover, due to the vascular state within the
tumor, a depiction of necrotic areas is also possible [29].
In contrast to the brief imaging examinations by fpVCT, data acqui-
sition by MRI, μCT, or ultrasound demands much longer scanning
times and, therefore, requires the maintenance of body temperature
and administration of anesthesia through inlet tubes for the mice. Pos-
itron emission tomography (PET) imaging assesses functional tumor
characteristics, such as glucose metabolism, as indirect markers for
the vitality of tumor tissues and provides information about blood flow
and blood volume [30]. However, only in combination with CT can
certain biologic processes be determined as PET can be correlated to
Figure 5. Comparison of growth kinetics and morphologic changes in both necrotic and nonnecrotic tumors analyzed by fpVCT imaging
in vivo. (A) Graphic representations of density distributions within a tumor with developing necrosis over time. The state of vasculari-
zation of this tumor is depicted in Figure 2A. At 21 days after implantation, a wide Gaussian curve in a negative HU range indicates a lack
of blood vessels in the mammary fat pad. After 4 weeks, a small bell-shaped curve with a homogeneous distribution of only one density
portion in a positive HU range is detectable. During days 35 and 42, the Gaussian distribution divides into two components, one of low
density (developing necrosis) and one of higher density (tumor tissue and contrast agent–containing blood vessels). (B) Corresponding
serial sections of the 3D visualization of the tumor were generated using fpVCT. Similar to the corresponding histograms (A), necrotic
tissue developed regularly (blue) and displaced intact tumor tissue (red). Surrounding blood vessels (white) detected by contrast agent
only occur in the tumor periphery (B, bottom). (C) The histograms for the nonnecrotic tumor showed no movement into the negative HU
range between days 20, 25, 28, and 31, although the curve spreads at the latest time point because of an increase of different density
portions. (D) Corresponding serial sections of the 3D visualization of the tumor are shown. As depicted in the corresponding histograms,
no central area of necrosis was observed in this tumor over time.
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anatomic structures. The use of PET is also rather expensive because it
depends on short-lived isotopes and requires a cyclotron and nearby
radiochemistry facilities [31]. Imaging by fpVCT reliably mirrors the
structural alterations within the different mammary carcinomas, in-
cluding the spreading and loss of contrast agent–containing blood ves-
sels during the course of tumor progression.
After 5 weeks of monitoring orthotopically implanted tumors us-
ing fpVCT, the vessel density within the center of the tumor appears
to be reduced, clearly the first sign of the development of central ne-
crosis. Simultaneously, the broadening of vessel diameters around the
tumor suggested the enhanced permeability of the vessels, resulting
in a rapid discharge of iodine-containing contrast agent into the in-
terstitial space as shown previously [11]. The enhanced permeability
of vessels together with abnormal endothelial stratification and al-
tered basement membranes, arteriovenous shunts, and blind ends
are characteristic features of tumor-induced vascularization [32]. In
contrast, the subcutaneous tumors continuously recruit increasing
peripheral and inner tumor vessels during the observation period.
Furthermore, they develop a close lattice of vessels through the tu-
mor, allowing sufficient blood supply to prevent the development of
central necrosis.
It has previously been shown that the application of iodine-containing
contrast agents during μCT and fpVCT scans allow the observation
of specific blood-flow distribution and blood supply [33]. Functional
characteristics of tumor vessels, such as permeability that results from
defective endothelial barrier function, in combination with high in-
terstitial pressures [34] or perfusion measurements of blood flow to
predict blood volume within a single vessel, can also be obtained us-
ing contrast-enhanced μCT [35,36].
One of the most challenging problems using fpVCT is the spatial
resolution, which, in our study, was limited to 150 to 200 μm. There-
fore, sizes and number of microvessels cannot be depicted by fpVCT
imaging. Due to the partial volume effect caused by the limited res-
olution of 150 μm, changes in microvessel density will only result in
an alteration in the normal tumor tissue compartment of the histo-
gram. Therefore, we propose that the quantitatively observed increase
in the high-density portion within the tumor volume is caused by a
dilatation of preexisting vessels. Here, we repeatedly administered an
Figure 6.Morphologic structures of both tumor types depicted by fpVCT compared with histopathologic analysis. (A and B) Overlays of the
histograms over time allowed the comparison of the shift of the curves during tumor development. (A) Necrotic tumor: 21 days after
orthotopic implantation of MDA-MB-231 cells, the tumor volume primarily consisted of low density, which is explained by its lack of re-
ceptivity toward the contrast agent. After 28 days, the histogram depicts the characteristic shift to the positive HU sector. At this time
point, the tumor consisted primarily of intact tumor tissue and had a threefold greater volume than the previous week. After days 35 and
42, the curve shifts progressively into the negative HU sector, suggestive of the development of necrosis. (B) Nonnecrotic tumor: 20 days
after subcutaneous implantation of R30C cells, the tumor volume primarily consisted of an area of relatively low density similar to the
necrotic tumor in (A) at the first time point. After 25 days, the tumor volume increased nearly twofold. Until day 28, a clear shift of the
graph to the positive HU sector remained throughout the peak of the curve; after 31 days, it shifts broadly in a negative direction. (C–H)
fpVCT–generated images of the necrotic tumor (C and E) and the homogeneous nonnecrotic tumor in situ (F and H). H&E–stained paraffin
sections of the tumors depict the distinct central area of necrosis of the orthotopically implanted tumor (D) and the generally intact tumor
tissue of the subcutaneous tumor (G). Note that the latter tumor grew in multiple lobes (F, arrow) and that only one lobe was analyzed in
detail (G and H). The predicted distributions of necrosis as illustrated in blue and the intact tissue as depicted in red within the tumors are
determined using fpVCT (E and H). Scale bars: D, 3 mm; E, 6 mm; G, 800 μm; H, 1600 μm.
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iodine-containing contrast agent at a concentration that was well tol-
erated in all mice. Smaller vessel diameters of 40 to 50 μm have been
visualized in tumors by Kiessling et al. [11] by applying higher doses
of iodine- or barium-containing contrast agents. However, this method
does not allow follow-up studies because of the high, and therefore
toxic, concentrations of these contrast agents. To optimize the spatial
resolution to visualize blood vessels, there is a strong need for blood-
pool contrast agents, such as the macromolecular media that remain
intravascular [37,38].
Such a development will bridge the gap between the high spatial
resolution of either light or scanning electron microscopy for the
analyses of microvessel architecture ex vivo [39–41] and the moderate
resolution of emerging imaging techniques for the dynamic, 3D,
in vivo morphogenic studies over time.
Our data show that fpVCT enables the quantitative determination
of various density portions that correlate to distinct tissue types within
a defined tumor volume. At present, data such as these have only
been obtained by both a time- and cost-intensive approximation due
to the analyses of serial histologic sections postmortem, which does
not allow the determination of the kinetics of necrotic progression.
Because the depiction of necrosis is dependent on the altered distribu-
tion of contrast agent, only strict compliance to standardized imaging
protocols will allow the obtainment of comparable and reproducible
data and, thereby, the exact delineation and quantification of different
tumor components. First, both the amount and time point of the ap-
plication of contrast agent must be equalized for each scan. Second,
the tumor must possess sufficient blood vessels, even in the periphery,
to avoid the dispersion of contrast agent within the area of necrosis
during the scan. A delay in scanning after the application of contrast
agent, as well as an increased permeation of contrast agent, will result
in the overestimation of viable tumor tissue. So far, the influence of
high intratumoral pressure on the uptake of contrast agent into the
tumor is unknown and will be the focus of further investigations. In
this study, however, histologic analysis confirmed that the reduced re-
ceptivity for contrast medium in the center of the tumor is due to cen-
tral necrosis.
During irradiation or antiangiogenic cancer treatment, effects on
the permeability of vessel walls, which might lead to an over- or un-
derestimation of single density portions such as necrosis, have to be
considered. To prevent misinterpretation of fpVCT data sets regard-
ing morphologic changes within the tumor, comparative analyses of
fpVCT images taken over time to early fpVCTexaminations, to con-
trols, and to histologic results are mandatory.
In summary, our study illustrates the ability of fpVCT under stan-
dard conditions to allow the precise and noninvasive quantification of
tumor growth and morphologic changes during the course of the dis-
ease. This imaging technique will thus limit the statistical variability of
preclinical studies, reduce the number of mice required for each study,
and increase the amount of data obtained from each animal. The novel
approach using fpVCT presented here is therefore both a useful and
cost-effective tool for the preclinical evaluation of anticancer therapies.
Furthermore, within the fast-growing field of oncological experiments
with genetically engineered mice, fpVCT imaging will provide unique,
valuable information on the role of single genes in tumor growth and
progression and in altered tumor vessel recruitment.
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